—

AstraZeneca PLC (AZN.L) — the peer cohort

As of 2026-11-10 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

AstraZeneca PLC ranks 9 of 11 in its cohort on the Closelooknet composite (55/100) — the cohort is led by Halozyme Therapeutics Inc at 70/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
AZN.L AstraZeneca PLC 55 60 75 44 info 10.2%
LLY Eli Lilly and Company 64 91 90 22 bull 2.8%
ORNAV.HE Orion Oyj A 63 94 84 29 ok 1.4%
ORNBV.HE Orion Oyj B 63 94 84 29 ok 1.4%
SAN.PA Sanofi SA 63 75 69 63 bull 0.7%
GSK GSK plc 55 54 78 54 info 14.8%
NVO Novo Nordisk A/S 55 28 86 72 neutral 33.1%
HALO Halozyme Therapeutics Inc 70 76 94 36 info 23.1%
ARGX.BR Argen-X 65 85 75 28 ok 6.6%
ONC BeOne Medicines AG 65 91 64 29 ok 0.2%
ANN.AU Ansell Ltd 64 97 48 50 ok 0.9%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-11-10

Quick answers

Who are AstraZeneca PLC's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Eli Lilly and Company (LLY), Orion Oyj A (ORNAV.HE), Orion Oyj B (ORNBV.HE), Sanofi SA (SAN.PA), GSK plc (GSK), Novo Nordisk A/S (NVO), Halozyme Therapeutics Inc (HALO), Argen-X (ARGX.BR) and others, as of 2026-11-10.

How does AZN.L score against its peers?

AstraZeneca PLC's composite reads 55/100, ranking 9 of 11 in its cohort as of 2026-11-10; the cohort's highest composite is Halozyme Therapeutics Inc at 70/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.